Mounir Ait-Khaled
GlaxoSmithKline
HIV Clinical Development and Medical Affairs Europe
Greenford
UK
Name/email consistency: high
- HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. Ait-Khaled, M., Rakik, A., Griffin, P., Stone, C., Richards, N., Thomas, D., Falloon, J., Tisdale, M. Antivir. Ther. (Lond.) (2003)